# OnCo record paper-fizazi-triton3-rucaparib-nejm-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-fizazi-triton3-rucaparib-nejm-2023" ;
  schema:name "TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer"@en ;
  schema:alternateName "TRITON3"@en, "Fizazi 2023 rucaparib randomised"@en ;
  schema:description "The randomised confirmation that a PARP inhibitor beats the alternatives in men with a BRCA fault, nearly doubling the time before the cancer grew on scans. In men with an ATM fault instead, it did nothing."@en ;
  schema:url <https://onco.cc/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/nejmoa2214676>, <https://pubmed.ncbi.nlm.nih.gov/36795891/>, <https://clinicaltrials.gov/study/NCT02975934> ;
  onco:tag "prostate-evidence" ;
  schema:sameAs <https://doi.org/10.1056/nejmoa2214676> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Fizazi K, Piulats JM, Reaume MN, et al." ;
  onco:related <https://onco.cc/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/>, <https://onco.cc/key-papers/paper-profound-nejm-2020/>, <https://onco.cc/key-papers/paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016/>, <https://onco.cc/roadmaps/prostate-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/atm/> ;
  onco:drugs <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/enzalutamide/> ;
  onco:companies <https://onco.cc/companies/clovis-oncology/> ;
  onco:terms <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/synthetic-lethality/>, <https://onco.cc/terms/genome-wide-loss-of-heterozygosity/>, <https://onco.cc/terms/radiographic-progression-free-survival/> ;
  onco:people <https://onco.cc/people/karim-fizazi/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-trial-enrolment/>, <https://onco.cc/bottlenecks/b-resistance/> ;
  onco:journals <https://onco.cc/journals/nejm/> .